Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Crossover Experiments01:16

Crossover Experiments

2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Group Design02:01

Group Design

8.9K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
8.9K
Randomized Experiments01:13

Randomized Experiments

6.8K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.8K
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

189
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
189
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

158
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
158

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame Topic

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Molecular therapy. Advances·2026
Same author

Characteristics of Crowdfunding Campaigns for Proton Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with Microsatellitosis.

Annals of surgical oncology·2026
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Information borrowing in phase II randomized dose-ranging clinical trials in oncology.

BMC medical research methodology·2026
Same author

The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Jun 12, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints.

Guillaume Mulier1, Sylvie Chevret1, Ruitao Lin2

  • 1INSERM U1153, Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation Assessments (ECSTRRA) Team, Paris, France.

Statistics in Biopharmaceutical Research
|September 20, 2024
PubMed
Summary

This study adapts the Bayesian optimal phase II (BOP2) design for multi-arm trials, efficiently evaluating multiple drugs simultaneously. The new design shows improved performance in both controlled and uncontrolled settings for phase II oncology trials.

Keywords:
BayesMulti-armOncologyPhase IIRandomization

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K

Related Experiment Videos

Last Updated: Jun 12, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmacological Research

Background:

  • Phase II clinical trials often face limited patient numbers, necessitating efficient evaluation of multiple drugs.
  • Simultaneous assessment of drug efficacy and toxicity is critical to avoid research waste.
  • Platform phase II trials offer a more efficient approach to screen multiple candidate drugs concurrently.

Purpose of the Study:

  • To adapt the Bayesian optimal phase II (BOP2) design for multi-arm clinical trials.
  • To enable simultaneous evaluation of multiple drugs in both uncontrolled and controlled phase II settings.
  • To develop a flexible monitoring threshold for adaptive trial designs.

Main Methods:

  • The study adapted the BOP2 design for multi-arm trials using a Dirichlet distribution to model binary efficacy and toxicity endpoints.
  • Posterior marginal distributions informed a dynamic, varying monitoring threshold throughout the trial.
  • Family-wise Type I error rate was controlled for multiple comparisons against a common reference or shared control.

Main Results:

  • Simulations demonstrated superior operating characteristics compared to designs with constant thresholds.
  • The proposed adaptive design showed reduced sensitivity to variations in patient accrual rates.
  • The BOP2 adaptation proved effective in both uncontrolled and controlled trial settings.

Conclusions:

  • The adapted BOP2 design offers a promising approach for phase II oncology trials evaluating multiple drugs.
  • This adaptive design enhances efficiency and statistical rigor in resource-limited trial settings.
  • The flexible thresholding strategy improves trial robustness and reliability.